AQR Capital Management
MRKR icon

AQR Capital Management’s Marker Therapeutics MRKR Stock Holding History

AQR Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,152
Closed -$116K – 2292
2021
Q2 		$116K Buy
+4,152
New +$109K ﹤0.01% 2183
2019
Q4 		– Sell
-1,961
Closed -$100K – 2154
2019
Q3 		$100K Buy
+1,961
New +$116K ﹤0.01% 2078

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

AQR Capital Management's MRKR Position: Q3 2021 in Review

AQR Capital Management sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 4,152 shares — an estimated $116K sold.

AQR Capital Management first reported a position in MRKR in Q3 2019 and held it in 2 quarters. The position peaked at $116K in Q2 2021. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

  • AQR Capital Management reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
  • AQR Capital Management sold 4,152 Marker Therapeutics shares in Q3 2021, an estimated $116K.
  • AQR Capital Management first reported a position in Marker Therapeutics in Q3 2019 and held it in 2 quarters.
  • AQR Capital Management's Marker Therapeutics position peaked at $116K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on AQR Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.